HDAC9 and hepatocellular carcinoma: Studies have shown that HDAC inhibitors restore FBP1 expression by mediating the reduction of H3K27Ac in the FBP1 enhancer, reduce glucose lowering and lactate secretion, and inhibit HCC cell growth and tumor growth in mice in vitro [47, 99], and it has been demonstrated that HDAC inhibitors such as tricotinostatin A (TSA), sodium butyrate (NaBu) [100], SAHA [101], and LBH589 [102],which can exert better effects in combination with 5AZA.